Shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) have earned an average rating of “Hold” from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $19.33.

A number of equities analysts have weighed in on AXDX shares. BidaskClub lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Friday, October 5th. JPMorgan Chase & Co. lowered Accelerate Diagnostics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $25.00 to $16.00 in a research note on Wednesday, November 7th. Zacks Investment Research upgraded Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Finally, ValuEngine lowered Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 27th.

In related news, Director Thomas D. Brown acquired 10,000 shares of Accelerate Diagnostics stock in a transaction on Wednesday, November 28th. The stock was acquired at an average price of $13.65 per share, for a total transaction of $136,500.00. Following the purchase, the director now owns 16,381 shares of the company’s stock, valued at approximately $223,600.65. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have acquired a total of 21,600 shares of company stock valued at $308,301 in the last quarter. Company insiders own 49.30% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SRS Capital Advisors Inc. acquired a new stake in shares of Accelerate Diagnostics during the 3rd quarter valued at about $115,000. HAP Trading LLC acquired a new stake in shares of Accelerate Diagnostics during the 3rd quarter valued at about $270,000. Man Group plc acquired a new stake in shares of Accelerate Diagnostics during the 3rd quarter valued at about $313,000. MetLife Investment Advisors LLC grew its position in shares of Accelerate Diagnostics by 59.1% during the 3rd quarter. MetLife Investment Advisors LLC now owns 18,052 shares of the medical research company’s stock valued at $414,000 after acquiring an additional 6,704 shares during the period. Finally, Trellus Management Company LLC acquired a new stake in shares of Accelerate Diagnostics during the 3rd quarter valued at about $566,000. Institutional investors and hedge funds own 48.52% of the company’s stock.

AXDX stock traded down $0.64 during midday trading on Friday, reaching $15.03. The stock had a trading volume of 539,300 shares, compared to its average volume of 464,237. The firm has a market capitalization of $815.69 million, a price-to-earnings ratio of -12.96 and a beta of 2.51. The company has a debt-to-equity ratio of 1.52, a current ratio of 35.26 and a quick ratio of 33.54. Accelerate Diagnostics has a 52-week low of $10.23 and a 52-week high of $30.35.

Accelerate Diagnostics (NASDAQ:AXDX) last issued its earnings results on Tuesday, November 6th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.41). The company had revenue of $1.36 million during the quarter, compared to analyst estimates of $2.89 million. Accelerate Diagnostics had a negative return on equity of 81.76% and a negative net margin of 1,365.75%. As a group, equities research analysts expect that Accelerate Diagnostics will post -1.61 earnings per share for the current year.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast.

Featured Article: Balance Sheet

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.